DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: OCREVUS (ocrelizumab)
*****************************************************
#Post#: 3213--------------------------------------------------
Fatal PML case in 78-year-old patient on Ocrevus monotherapy
By: agate Date: March 16, 2021, 5:55 pm
---------------------------------------------------------
From JAMA Neurology (March 16, 2021), "Progressive multifocal
leukoencephalopathy in a patient with progressive multiple
sclerosis treated with ocrelizumab monotherapy":
HTML http://bit.ly/3eQm9ii
#Post#: 3214--------------------------------------------------
MedPage Today) PML reported in ocrelizumab-treated MS patient
By: agate Date: March 18, 2021, 1:28 am
---------------------------------------------------------
From MedPage Today (March 17, 2021)--"PML reported in
ocrelizumab-treated MS patient":
HTML https://www.medpagetoday.com/neurology/multiplesclerosis/91647
#Post#: 3216--------------------------------------------------
(Medscape) First case of PML associated with ocrelizumab monothe
rapy
By: agate Date: March 20, 2021, 12:43 am
---------------------------------------------------------
This is the third article I've found on this topic, and so far
there is no indication of how long the patient had had MS. It
might be helpful to know that.
Medscape (March 29, 2021)--"First case of PML associated with
ocrelizumab monotherapy":
HTML https://www.medscape.com/viewarticle/947765#vp_2
#Post#: 3219--------------------------------------------------
Re: Fatal PML case in 78-year-old patient on Ocrevus monotherapy
By: agate Date: March 23, 2021, 1:10 am
---------------------------------------------------------
The first article mentioned in this thread contains this
information about the patient.
[quote][font=Guardian TextSans Web]The patient had been
diagnosed with MS almost 3 decades prior after developing
gradual gait dysfunction and bilateral asymmetric leg weakness
throughout several years. Despite continued slow gait worsening
over years, he had not been treated with immunotherapy until
ocrelizumab was approved by the US Food and Drug Administration
for primary progressive MS in 2017. He began taking ocrelizumab
at age 76 years soon after Food and Drug Administration
approval. The patient’s JCV index was 2.48 prior to initiation,
and the theoretical risk of PML was discussed prior to starting.
He tolerated the treatments well but continued to exhibit
worsening gait dysfunction.[/font][/quote][font=Guardian
TextSans Web][/font]
[font=Guardian TextSans Web][/size][/font]
[font=Guardian TextSans Web][/size]One wonders why a patient of
76 who has had PPMS for some 30 years would have been prescribed
ocrelizumab.[/font]
*****************************************************